2019 China BioMed Innovation and Investment Conference (2019 CBIIC) will be held in September 21-23 in Suzhou

CBIIC is located in the beautiful Suzhou. Over the past three years, centering on the principle of “promote the linkage between social capital and pharmaceutical innovation, improve innovation capability of pharmaceutical industry”, CBIIC has built a bridge of direct communication among entrepreneurs, investors, top experts, scholars and the government to promote the integration between pharmaceutical innovation and investment at home and abroad, facilitate the transformation of innovative achievements, enhance the cooperation and communication in pharmaceutical innovation industry in China and global and lead the pharmaceutical industry into the new era.

Since the 2016, CBIIC has started the new era of the communication between pharmaceutical innovation and investment, its widely covered field, high level of profession, international standards and suitability for the industrial needs has attracted extensive participation and recognition of domestic and foreign experts, investors, entrepreneurs and industrial leaders. The scale and influence of CBIIC is growing fast to make it become an international and influential conference with the highest industry specifications. From 2016 to 2018, the CBIIC has gain tremendous development in its scale. The number of the participants has increased from 1,500 to over 3,000. In 2018 CBIIC, there were 236 representatives from over 200 international organizations. As for the on-site roadshow projects, the number has increased from 68 to 129. In addition, there were 39 roadshow projects from Hong Kong, Taiwan and Macao and abroad, 41 off-site roadshow projects presented in 2018 CBIIC. CBIIC is making unremitting endeavor with domestic and foreign experts, investors, and enterprises to walk into the world stage.

Attractions of CBIIC

1. World famous enterprises and organizations as organizers and supporters

The organizers of CBIIC includes China Pharmaceutical Innovation and Research Development Association (PhIRDA), China Association for Medical Devices Industry (CAMDI), Chinese Hospital Association (CHA), Hong Kong Exchanges and Clearing Limited (HKEX) and Securities Association of China (SAC).

The supporters of CBIIC includes the Development Center of Medical Science and Technology of National Health and Family Planning Commission of the People’s Republic of China, China Academy of Medical Sciences, China Academy of Chinese Medical Sciences, Bureau of Science & Technology for Development of Chinese Academy of Sciences, NMPA Southern Medicine Economic Research Institute, Suzhou Industrial Park, China Industry Technology Innovation Strategic Alliance, Australian Trade and Investment Commission (Austrade), Government of British Columbia of Canada, National Foundation for Cancer Research (NFCR), Institute for Biotechnology and Medicine Industry (IBMI), Hong Kong Bio-Med Innotech Association (HKBMIA), Chinese Securities Association of Hong Kong, Japan Pharmaceutical Manufacturers Association (JPMA), Bio Century, China Association of Enterprises with Foreign Investment R&D-based Pharmaceutical Association Committee (RDPAC) and TMX Group Limited. In addition, J.P. Morgan is the Exclusive International Financial Institution Sponsor of CBIIC.

2. Domestic and Foreign KOLs

CBIIC invited domestic and foreign government officials, experts from pharmaceutical and investment industry and academicians as the keynote speakers to analyse the newest trend and policies of global pharmaceutical and investment development and share the experiences of pharmaceutical innovation and successful merging case to tighten the relationship between pharmaceutical innovation and social capital. During the conference, participants can share different ideas and successful experience to build communication and Win-Win cooperation. The interactions among participants can facilitate the progress of the transition of the innovative projects and also speed up the development of pharmaceutical innovation industry, which results in creating the standards and making great contribution to the whole industry.

3. More than 10 Excellent Parallel Sessions to Meet Diversified Needs

With the 3 years’ successful experience, CBIIC set up the Opening Ceremony, Clinical-Trial Data Release of Innovative Drugs, Listed Company Roadshow, Non-Listed Company Roadshow, Medical Devices Roadshow, International Roadshow, Artificial Intelligence Roadshow, Rare Diseases and Orphan Drugs Roadshow, Investors’ Experience Sharing Forum, Cross-Border M&A Forum, Analyze of Pharmaceutical Policies, Closed-Door meetings and different salons that focus on global pharmaceutical R&D trends and new direction of pharmaceutical investment. PhIRDA will keep exploring and expanding featured and new fields with innovative format and services, to follow the trend of the industry and fulfill the participants’ need.

4. Domestic and Foreign Authoritative Media’s Report

Each year’s CBIIC had attracted lots of media including the international popular journal like the Nature, pharmaceutical media like Health.people.cn, Medicine Economic Reporter, and MENET and financial media such as the Economic Information Daily, 21st Century Business Herald, and YICAI Daily, who had also witnessed and reported the annual brand event at home and abroad.